abiraterone combined with dalpiciclib

Phase 2

SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

abiraterone combined with dalpiciclib is one of 15 therapeutic programs targeting Salivary Gland Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Salivary Gland CarcinomaRecruiting

Salivary Gland CarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

16 competitors in Salivary Gland Carcinoma

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Opdivo

2 3

Keytruda

Merck & Co.

Phase 2

1 4

Nubeqa

Bayer

Phase 2

1 5

Padcev

Pfizer

Phase 2

1 6

Zoladex

TTerSera Therapeutics LLC

Phase 2

1 7

Zoladex

TTerSera Therapeutics LLC

Phase 2

1 8

PARP Inhibitor

HHellenic Cooperative Oncology Group

Phase 2

1 9

SHR-A1921

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

1 10

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2Recruiting

Salivary Gland Carcinoma

NCT07815522

Clinical

Trials by Indication[1]

Salivary Gland Carcinoma1 trial

A Prospective, Open-Label, Single-Arm, Phase II Clinical Study of Abiraterone Combined With Dalpiciclib in Patients With HER-2-Negative, AR-Positive Recurrent/Metastatic Salivary Gland Carcinoma

Recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT07815522·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for abiraterone combined with dalpiciclib. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for abiraterone combined with dalpiciclib. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

abiraterone combined with dalpiciclib

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Salivary Gland Carcinoma1 trial

References

Drug Info

Quick Facts

Related News